Warner-Lambert
In 2000, Warner-Lambert merged with Pfizer[1]
Warner-Lambert was listed as a client of business intelligence firm Business Insights[2]
Crimes
In 2004, Warner Lambert agreed to plead guilty and pay more than $430 million to resolve criminal charges and civil liabilities in connection with its illegal and fraudulent promotion of unapproved uses for its drug Neurontin[3]. The U.S. department of Justice report that 'Warner-Lambert's strategic marketing plans, as well as other evidence, show that Neurontin was aggressively marketed to treat a wide array of ailments for which the drug was not approved'. They go on to add that Warner-Lambert promoted Neurontin even when scientific studies had shown that it was not effective and for uses that had been specifically rejected by the FDA.
References
- ↑ BBC News Drugs Giants Merge Accessed 12th February 2008
- ↑ Business Insights Patient Power: The shift towards more informed, more powerful consumers of drugs Accessed 5th February 2008
- ↑ U.S. Department of Justice WARNER-LAMBERT TO PAY $430 MILLION TO RESOLVE CRIMINAL & CIVIL HEALTH CARE LIABILITY RELATING TO OFF-LABEL PROMOTION Accessed 12th february 2008
